|
⚲
|
| Keyboard |
| Birchview Capital LP
✚
|
|
|---|---|
| CRD # | 170534 |
| SEC # | 801-79710 |
| CIK # | 0001618205 |
| AUM | 239.1 M (2026-03-31) |
| Employees | 6 (83% Investors, 0% Brokers) |
| Fees | |
| Minimum | |
| Phone | 802-923-3826 |
| Address | 688 Pine Street Burlington, VT 05401 |
| Source | [IAPD] [EDGAR] [Website] |
| Total AUM ($M) |
|---|
| CIK | Period |
|---|---|
| 0001618205 |
| Sector | Form 13F Holdings | Value ($M) |
|---|---|---|
| KLA Tencor Corp | 29.3 | |
| Bristol Myers Squibb Co | 18.6 | |
| Olivia Ventures Inc | 7.8 | |
| Lam Research Corp | 7.7 | |
| Stoke Therapeutics Inc | 6.8 | |
| Ovintiv Inc | 6.4 | |
| Intellia Therapeutics Inc | 5.7 | |
| Structure Therapeutics Inc | 4.8 | |
| Quidelortho Corp | 4.8 | |
| Solid Biosciences Inc | 4.5 | |
| Prothena Corp PLC | 4.4 | |
| Biodesix Inc | 4.2 | |
| Acadia Pharmaceuticals Inc | 3.8 | |
| Protagonist Therapeutics Inc | 3.7 | |
| Neurocrine Biosciences Inc | 3.6 | |
| Olema Pharmaceuticals Inc | 3.3 | |
| Camp Nine Inc | 2.8 | |
| Ocular Therapeutix Inc | 2.7 | |
| United Therapeutics Corp | 2.7 | |
| Nektar Therapeutics | 2.2 | |
| Celldex Therapeutics Inc | 2.2 | |
| Novocure Ltd | 2.2 | |
| EQT Corp | 2.2 | |
| Phathom Pharmaceuticals Inc | 2.2 | |
| Bicycle Therapeutics PLC | 2.2 | |
| Compass Pathways PLC | 2.1 | |
| Pacific Biosciences of California Inc | 2.0 | |
| Cytokinetics Inc | 2.0 | |
| Corcept Therapeutics Inc | 1.9 | |
| Vera Therapeutics Inc | 1.8 | Prev | Page 1 | Next |
| Type | Form D Funds | Date | Sold | AUM |
|---|---|---|---|---|
| PE | Monteris BC Holdings 6 LLC | [2023-03-22] | 1.5 M | 2.5 M |
| Filed 2022-06-01 (D) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Monteris BC Holdings 7 LLC | [2023-03-22] | 5.5 M | 3.8 M |
| Filed 2024-08-29 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose | ||||
| PE | Birchview Capital VF III LLC | [2021-09-29] | 3.5 M | 4.2 M |
| Filed 2022-06-02 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Monteris BC Holdings 5 LLC | [2021-03-30] | 29.7 M | 4.2 M |
| Filed 2022-08-15 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Monteris BC Holdings 4 LLC | [2020-06-12] | 3.0 M | 0.0 M |
| Filed 2022-05-17 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Ed BC Holdings 3 LLC | [2020-03-30] | 8.1 M | 0.0 M |
| Filed 2021-10-29 (D/A) · Exemption 506(b) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Monteris BC Holdings 3 LLC | [2019-03-20] | 6.6 M | 0.0 M |
| Filed 2020-10-02 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Remaining Indefinite · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Monteris BC Holdings 2 LLC | [2017-08-24] | 4.3 M | 0.0 M |
| Offered $4,286,455 · Filed 2020-06-15 (D/A) · Exemption 506(b), 3(c), 3(c)(1) · Minimum $10,000 · Duration More than one year · Revenue Decline to Disclose | ||||
| PE | Ed BC Holdings LLC | [2017-03-31] | 0.6 M | 0.0 M |
| Offered $570,000 · Filed 2016-09-22 (D) · Exemption 506(b) · Minimum $5,700 · Duration One year or less · Revenue Decline to Disclose | ||||
| PE | Monteris BC Note LLC | [2017-03-31] | 6.2 M | 0.0 M |
| Offered $6,162,745 · Filed 2017-01-31 (D/A) · Exemption 506(b) · Minimum $5,516 · Duration One year or less · Revenue Decline to Disclose | ||||
| View All | ||||
| AUM Breakdown | Accounts | AUM ($M) |
|---|---|---|
| By Client Type | ||
| (a) Individuals (other than high net worth individuals) | 0 | 0.7 |
| (b) Individuals (high net worth individuals) | 0 | 126.1 |
| (c) Banking or thrift institutions | 0 | 0.0 |
| (d) Investment companies | 0 | 0.0 |
| (e) Business development companies | 0 | 0.0 |
| (f) Pooled investment vehicles | 12 | 112.3 |
| (g) Pension and profit sharing plans | 0 | 0.0 |
| (h) Charitable organizations | 0 | 0.0 |
| (i) State or municipal government entities | 0 | 0.0 |
| (j) Other investment advisers | 0 | 0.0 |
| (k) Insurance companies | 0 | 0.0 |
| (l) Sovereign wealth funds and foreign official institutions | 0 | 0.0 |
| (m) Corporations or other businesses not listed above | 0 | 0.0 |
| (n) Other | 0 | 0.0 |
| Total | 16 | 239.1 |
| By Discretionary | ||
| Discretionary | 16 | 239.1 |
| Non-Discretionary | 0 | 0.0 |
| Total | 16 | 239.1 |
| By Non-United States Persons | ||
| Non-United States Persons | 0.0 | |
| United States Persons | 239.1 | |
| Total | 16 | 239.1 |
| Form D Directors | Role | # Filings | # Firms | 2011 - 2026 |
|---|---|---|---|---|
| Jack Schuler | Executive Officer | 45 | 2 | |
| Matthew Strobeck | Executive Officer | 37 | 2 | |
| Birchview Capital LP | Executive Officer, Promoter | 10 | 2 | |
| Richard McCormick | Executive Officer | 6 | 2 | |
| Birchview Partners LLC | Promoter | 2 | 2 | |
| William Scully | Executive Officer | 1 | 1 |
| EDGAR Form | CIK | 2011 - 2026 |
|---|---|---|
| 13F-HR | [0001618205] | |
| 3 | [0001618205] | |
| 4 | [0001618205] | |
| SC 13G | [0001618205] |
| Form 13D/13G Filer | Form 13D/13G Subject | Filed |
|---|---|---|
| Birchview Capital LP | Aziyo Biologics Inc | [2021-12-17] |
| Birchview Capital LP | Soleno Therapeutics Inc | [2017-12-26] |
| Birchview Capital LP | Hansen Medical Inc | [2015-03-19] |
| Firm Profile (Form ADV) | |
|---|---|
| Discretionary AUM | $0.2B |
| Serves | Institutional, Retail |
| Fund Types | Hedge Fund, Private Equity |
| Form 3/4/5 Subject | 2011 - 2026 |
|---|---|
| Birchview Fund LLC | |
| Strobeck Matthew | |
| Elutia Inc | |
| Birchview Capital LP | |
| Birchview Partners LLC | |
| Birchview Capital GP LLC | |
| Yield10 Bioscience Inc |
| Insider Transaction (Form 3/4/5) | Date | Action | Shares | Price | Value ($) |
|---|---|---|---|---|---|
|
Elutia Inc AZYO
Class A Common Stock
|
2023-03-27 | Buy | 10,000 | $1.59 | 15,900 |
|
Elutia Inc AZYO
Class A Common Stock
|
2023-03-24 | Buy | 18,000 | $1.35 | 24,300 |
|
Elutia Inc AZYO
Class A Common Stock
|
2023-03-24 | Buy | 2,000 | $1.35 | 2,700 |
|
Elutia Inc AZYO
Class A Common Stock
|
2023-03-23 | Buy | 10,000 | $1.49 | 14,900 |
|
Elutia Inc AZYO
Class A Common Stock
|
2023-03-23 | Buy | 100,000 | $1.49 | 149,000 |
|
Elutia Inc AZYO
Class A Common Stock
|
2022-12-08 | Buy | 4,000 | $3.79 | 15,160 |
|
Elutia Inc AZYO
Class A Common Stock
|
2022-12-08 | Buy | 9,061 | $3.79 | 34,341 |
|
Elutia Inc AZYO
Class A Common Stock
|
2022-12-07 | Buy | 10,000 | $3.58 | 35,800 |
|
Elutia Inc AZYO
Class A Common Stock
|
2022-12-07 | Buy | 34,000 | $3.58 | 121,720 |
|
Elutia Inc AZYO
Class A Common Stock
|
2022-12-01 | Buy | 40,000 | $4.75 | 190,000 |
|
Elutia Inc AZYO
Class A Common Stock
|
2022-05-11 | Buy | 200 | $5.96 | 1,192 |
|
Yield10 Bioscience Inc MBLX
Common Stock Warrants · derivative
|
2015-06-19 | Buy | 39,330 | $0.13 | 5,113 |
|
Yield10 Bioscience Inc MBLX
Common Stock
|
2015-06-19 | Buy | 43,700 | $3.32 | 145,084 |
|
Yield10 Bioscience Inc MBLX
Common Stock
|
2014-10-30 | Conversion | 2,000,000 | ||
|
Yield10 Bioscience Inc MBLX
Series B Convertible Preferred Stock · derivative
|
2014-10-30 | Conversion | 2,000 |
| Comparable Firms | State | AUM |
|---|---|---|
|
Compass Financial Advisors LLC
✚
|
IN | 282.5 M |
|
Hallador Investment Advisors Inc
✚
|
NV | 270.7 M |
|
Fuller Investment Management Company
✚
|
CA | 264.5 M |
|
ELCO Management Company LLC
✚
|
NY | 261.2 M |
|
Zephyr Management LP
✚
|
NY | 256.3 M |
|
Vantage Consulting Group Inc
✚
|
VA | 241.7 M |
|
Welcy Capital Advisors LLC
✚
|
FL | 225.7 M |
|
Open Field Capital LLC
✚
|
NY | 208.1 M |
|
MB Family Advisors LLC
✚
|
NY | 204.1 M |
|
CIG Asset Management Inc
✚
|
MI | 192.5 M |